JGC
RIGL icon

J. Goldman & Co’s Rigel Pharmaceuticals RIGL Stock Holding History

J. Goldman & Co’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,200
Closed -$672K – 511
2020
Q4 		$672K Buy
+19,200
New +$556K 0.03% 265
2018
Q1 		– Sell
-1,990
Closed -$77K – 422
2017
Q4 		$77K Buy
+1,990
New +$75.7K ﹤0.01% 305
2016
Q4 		– Sell
-39,060
Closed -$1.43M – 371
2016
Q3 		$1.43M Buy
+39,060
New +$1.12M 0.08% 215

Other funds holding RIGL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

J. Goldman & Co's RIGL Position: Q4 2023 in Review

J. Goldman & Co sold out of Rigel Pharmaceuticals (RIGL) in Q4 2023, closing a stake of 2,984 shares — an estimated $32.2K sold.

J. Goldman & Co first reported a position in RIGL in Q1 2016 and held it in 24 quarters. The position peaked at $3.83M in Q4 2017. 112 funds tracked by Wall St. Rank hold RIGL as of Q4 2023.

  • J. Goldman & Co reported no remaining Rigel Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 2,984 Rigel Pharmaceuticals shares in Q4 2023, an estimated $32.2K.
  • J. Goldman & Co first reported a position in Rigel Pharmaceuticals in Q1 2016 and held it in 24 quarters.
  • J. Goldman & Co's Rigel Pharmaceuticals position peaked at $3.83M in Q4 2017.
  • 112 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.